Gross Profit Comparison: Regeneron Pharmaceuticals, Inc. and Alkermes plc Trends

Biotech Giants' Profit Trends: Regeneron vs. Alkermes

__timestampAlkermes plcRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141709140002614539000
Thursday, January 1, 20151449420003711019000
Friday, January 1, 20162264240004560733000
Sunday, January 1, 20173357370005475166000
Monday, January 1, 20184924480006276700000
Tuesday, January 1, 20194777290007081200000
Wednesday, January 1, 20204658520007377200000
Friday, January 1, 202156983800013634200000
Saturday, January 1, 202289368700010612500000
Sunday, January 1, 2023141036800011301400000
Monday, January 1, 2024131230100012231500000
Loading chart...

Unleashing the power of data

A Tale of Two Biotech Giants: Regeneron vs. Alkermes

In the dynamic world of biotechnology, financial performance is a key indicator of a company's success and innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Alkermes plc have showcased contrasting trajectories in their gross profit trends. From 2014 to 2023, Regeneron has consistently outperformed Alkermes, with its gross profit peaking at over 13 billion in 2021, a staggering 420% increase from 2014. In contrast, Alkermes, while showing growth, reached its highest gross profit of approximately 1.4 billion in 2023, marking a 726% increase from its 2014 figures. This comparison highlights Regeneron's robust market position and innovative prowess, while Alkermes demonstrates steady growth and resilience. As the biotech industry continues to evolve, these trends offer valuable insights into the strategic directions and market dynamics of these two influential players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025